PUBLISHER: The Business Research Company | PRODUCT CODE: 1942517
PUBLISHER: The Business Research Company | PRODUCT CODE: 1942517
Cardiac markers are biomolecules released into the bloodstream in response to heart muscle damage or stress, serving as crucial tools for diagnosing and monitoring a spectrum of cardiac ailments such as heart attacks, angina, and heart failure.
The primary types of cardiac markers encompass troponin, creatine kinase-MB (CK-MB), B-type natriuretic peptide (BNP), myoglobin, and various other biomarkers. Troponin, a protein released upon heart muscle damage, stands as a pivotal marker widely used for diagnosing and monitoring heart-related conditions. Diverse products in the realm of cardiac markers include reagents, instruments, and various detection methodologies such as chemiluminescence, immunofluorescence, immunochromatography, and ELISA. These markers find application across multiple indications, including myocardial infarction, congestive heart failure, acute coronary syndrome, among others. End users encompass laboratory testing facilities, hospital labs, reference labs, contract testing labs, point-of-care testing facilities, and academic institutions, where these markers play a vital role in cardiac diagnostics and monitoring.
Tariffs are impacting the cardiac marker market by increasing costs of imported reagents, analytical instruments, chemiluminescence systems, and assay consumables. Hospital labs and reference laboratories in North America and Europe are most affected due to high import dependency, while Asia-Pacific experiences cost pressures on diagnostic manufacturing. These tariffs are increasing per-test costs and slowing system upgrades. However, they are also encouraging domestic production of reagents, local instrument assembly, and development of cost-efficient cardiac testing platforms.
The cardiac marker market research report is one of a series of new reports from The Business Research Company that provides cardiac marker market statistics, including cardiac marker industry global market size, regional shares, competitors with a cardiac marker market share, detailed cardiac marker market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac marker industry. This cardiac marker market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cardiac marker market size has grown rapidly in recent years. It will grow from $12.38 billion in 2025 to $13.95 billion in 2026 at a compound annual growth rate (CAGR) of 12.7%. The growth in the historic period can be attributed to increasing burden of cardiovascular diseases, expansion of hospital laboratory infrastructure, rising use of emergency cardiac testing, growing reliance on biomarker-based diagnosis, improvements in assay sensitivity.
The cardiac marker market size is expected to see rapid growth in the next few years. It will grow to $22.7 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to increasing demand for faster turnaround diagnostic tests, rising integration of cardiac diagnostics with digital platforms, expansion of point-of-care testing facilities, growing adoption of advanced biomarker panels, increasing focus on precision cardiology. Major trends in the forecast period include increasing use of high-specificity cardiac marker panels, rising adoption of automated immunoassay systems, growing demand for rapid cardiac diagnosis, expansion of multiparametric testing approaches, enhanced focus on clinical decision support.
The projected surge in the cardiac marker market is strongly driven by the escalating prevalence of cardiac diseases. This category comprises conditions affecting the heart's structure or functionality, leading to a spectrum of medical issues. Cardiac markers serve as crucial tools in diagnosing and monitoring various heart-related conditions such as heart attacks, angina, heart failure, and other cardiovascular diseases. Consequently, the demand for diagnostic tests involving cardiac markers has seen a notable increase. For instance, the British Heart Foundation reported an alarming increase of 30,000 deaths from coronary heart disease in England from the pandemic's onset to August 2022. Moreover, a staggering 346,000 individuals were on cardiac waiting lists by August 2022. Hence, the escalating prevalence of cardiac diseases significantly fuels the growth of the cardiac marker market.
Leading companies in the cardiac marker market prioritize innovative products, such as high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers, to drive market revenue. These biomarkers play crucial roles in diagnosing, categorizing, and treating cardiovascular ailments. For instance, in October 2023, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., a prominent China-based medical equipment and solutions provider, launched troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The hs-cTn assay surpasses minimal sensitivity, accuracy, and reliability requirements, aiding in identifying myocardial damage. These advanced products aim to enhance treatment approaches for cardiovascular diseases, offering dependable solutions to improve patient outcomes in both cardiovascular and related health contexts.
In April 2023, Abbott Laboratories, a US-based healthcare company acquired Cardiovascular Systems Inc. for an undisclosed amount. With this acquisition, Abbott will be able to better serve patients with peripheral and coronary artery disease by offering a novel and cutting-edge therapy for those with complicated cardiovascular disease. Through this acquisition, Abbott is able to expand the range of cutting-edge vascular devices it offers doctors, giving them more resources to assist patients. Cardiovascular Systems Inc. a US-based medical technology company.
Major companies operating in the cardiac marker market are Abbott Laboratories, F Hoffmann-La Roche AG, Siemens Healthineers AG, Danaher Corporation, Thermo Fisher Scientific Inc, bioMerieux SA, Bio-Rad Laboratories Inc, Beckman Coulter Inc, QuidelOrtho Corporation, Randox Laboratories Ltd, DiaSorin SpA, Tosoh Corporation, PerkinElmer Inc, Sysmex Corporation, Mindray Bio-Medical Electronics Co Ltd, Lepu Medical Technology Beijing Co Ltd, Trinity Biotech plc, Fujirebio Holdings Inc, Euroimmun AG, Abcam plc, Creative Diagnostics
North America was the largest region in the cardiac marker market in 2025. The regions covered in the cardiac marker market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the cardiac marker market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The cardiac marker market consists of sales of C-reactive protein (CRP) and Ischemia-modified albumin (IMA). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cardiac Marker Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses cardiac marker market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for cardiac marker ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cardiac marker market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.